Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803)

Docetaxel plus cisplatin and docetaxel plus irinotecan are active and well-tolerated chemotherapy regimens for advanced non-small-cell lung cancer (NSCLC). A randomised phase II study compared their efficacy and toxicity in 108 patients with stage IIIb/IV NSCLC, who were randomised to receive doceta...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, N, Fukuoka, M, Negoro, S-I, Nakagawa, K, Saito, H, Matsui, K, Kawahara, M, Senba, H, Takada, Y, Kudoh, S, Nakano, T, Katakami, N, Sugiura, T, Hoso, T, Ariyoshi, Y
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395326/
https://www.ncbi.nlm.nih.gov/pubmed/14710212
http://dx.doi.org/10.1038/sj.bjc.6601462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395326/
https://www.ncbi.nlm.nih.gov/pubmed/14710212
http://dx.doi.org/10.1038/sj.bjc.6601462

Ejemplares similares